Mitsubishi UFJ Trust & Banking Corp reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,783 shares of the medical research company's stock after selling 3,826 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp's holdings in IQVIA were worth $16,071,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares in the last quarter. FMR LLC raised its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares during the last quarter. Cantillon Capital Management LLC raised its position in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock worth $406,018,000 after purchasing an additional 226,017 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
IQV has been the subject of several recent analyst reports. Bank of America decreased their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Robert W. Baird reduced their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price objective on the stock. Finally, William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $249.05.
View Our Latest Report on IQV
IQVIA Price Performance
Shares of IQVIA stock traded down $4.72 on Tuesday, hitting $171.59. 602,879 shares of the company traded hands, compared to its average volume of 1,468,376. The business has a 50-day simple moving average of $192.73 and a 200 day simple moving average of $205.61. IQVIA Holdings Inc. has a 52 week low of $169.37 and a 52 week high of $252.88. The stock has a market capitalization of $30.25 billion, a P/E ratio of 22.88, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
